The UNM Cancer Center requests support of two clinical investigator faculty members who are major contributors to the programmatic and translational activities of the Center. We have highlighted their roles in facilitating the clinical components of the Center. Authorship of clinical trials, accrual of patients on interventional trials and leadership roles in cooperative group studies are particular areas of concentration Dr. Rabinowitz is currently an Associate Professor and Director of the University of New Mexico Cancer Center Clinic. He obtained his MD in 1984 at the University of Witwatersrand Medical School, in Johannesburg, South Africa. He completed a Residency in Internal Medicine, at Vanderbilt University in 1989, and then a fellowship in Hematology-Oncology, at Washington University in St. Louis in 1992. He joined the faculty of the UNM Cancer Center in 1997 as an Assistant Professor, and was promoted to Associate Professor in 2004. Dr. Winter is currently Professor and Chief of Pediatric Hematology-Oncology at the University of New Mexico Health Science Center. He received his MD from the University of Wisconsin, and then trained in Pediatrics at the University of New Mexico. He then completed a Fellowship in Pediatric Hematology-Oncology at Duke University Medical Center. He joined the faculty of the Department of Pediatrics at the University of New Mexico Health Science Center in 1998. He was appointed the Chief of the Division of Pediatric Hematology-Oncology in 2008, and was awarded the T. John Gribble Endowed Chair in 2009. Both of these clinical investigators play essential roles in the programmatic clinical research of the UNM Cancer Center.
The Clinical Staff Investigators ensure that the Center has experienced clinical faculty in leadership and authorship of clinical trials, to improve accrual of patients on interventional trials, and enhance leadership in cooperative group studies as well as mentoring junior faculty in these areas.
Zheng, Handong; Wu, Dandan; Wu, Xiang et al. (2018) Leptin Promotes Allergic Airway Inflammation through Targeting the Unfolded Protein Response Pathway. Sci Rep 8:8905 |
Ray, Anita L; Berggren, Kiersten L; Restrepo Cruz, Sebastian et al. (2018) Inhibition of MK2 suppresses IL-1?, IL-6, and TNF-?-dependent colorectal cancer growth. Int J Cancer 142:1702-1711 |
Hudson, Laurie G; Gillette, Jennifer M; Kang, Huining et al. (2018) Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase. Cancers (Basel) 10: |
Licon-Munoz, Yamhilette; Fordyce, Colleen A; Hayek, Summer Raines et al. (2018) V-ATPase-dependent repression of androgen receptor in prostate cancer cells. Oncotarget 9:28921-28934 |
Palsuledesai, Charuta C; Surviladze, Zurab; Waller, Anna et al. (2018) Activation of Rho Family GTPases by Small Molecules. ACS Chem Biol 13:1514-1524 |
Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546 |
Kumar, Suresh; Jain, Ashish; Farzam, Farzin et al. (2018) Mechanism of Stx17 recruitment to autophagosomes via IRGM and mammalian Atg8 proteins. J Cell Biol 217:997-1013 |
Vicuña, Belinda; Delaney, Harold D; Flores, Kristina G et al. (2018) Preferences for multigene panel testing for hereditary breast cancer risk among ethnically diverse BRCA-uninformative families. J Community Genet 9:81-92 |
Feng, Bing; Hoskins, William; Zhang, Yan et al. (2018) Bi-stream CNN Down Syndrome screening model based on genotyping array. BMC Med Genomics 11:105 |
Phinney, Brandon B; Ray, Anita L; Peretti, Amanda S et al. (2018) MK2 Regulates Macrophage Chemokine Activity and Recruitment to Promote Colon Tumor Growth. Front Immunol 9:1857 |
Showing the most recent 10 out of 344 publications